Spruce Biosciences(SPRB) - 2025 Q4 - Annual Report

Drug Development and Approval - TA-ERT is intended as an enzyme replacement therapy for Mucopolysaccharidosis Type IIIB (MPS IIIB), aiming to restore rhNAGLU enzyme activity in the central nervous system [20]. - The company plans to seek U.S. accelerated approval for TA-ERT based on existing clinical data and will initiate a confirmatory trial as a condition for the biologics license application (BLA) [21]. - TA-ERT has received multiple designations including Rare Pediatric Disease Designation, Fast Track Designation, Breakthrough Therapy Designation, and Orphan Drug Designation in the U.S. and EU [41]. - The FDA confirmed that CSF HS-NRE is a surrogate biomarker likely to predict clinical benefit, which could support accelerated approval for TA-ERT [35]. - The company anticipates submitting the BLA for TA-ERT in Q4 2026, following the FDA's requirements for drug product process performance qualification [39]. - The FDA requires satisfactory completion of an advisory committee review and approval of the NDA or BLA before any commercial marketing of the product in the U.S. [88]. - Phase 1 clinical trials focus on safety, dosage tolerance, and early evidence of effectiveness, often involving healthy subjects or patients with severe diseases [89]. - Phase 2 trials evaluate the drug in a limited patient population to identify adverse effects and preliminarily assess efficacy [89]. - Phase 3 trials are conducted to establish the overall benefit/risk ratio and typically require two well-controlled trials for FDA approval [89]. - The FDA aims to review and act on standard NDAs or BLAs within ten months from the filing date, although this process often takes longer due to additional information requests [94]. - Accelerated approval may be granted for drugs treating serious conditions based on surrogate endpoints, contingent on post-approval confirmatory studies [99]. - The FDA may require Phase 4 testing to monitor the effects of approved products and ensure ongoing safety and efficacy [106]. - The company must demonstrate safety and efficacy to regulatory authorities, which is a lengthy and complex process that may delay commercialization [192]. - Regulatory approval for product candidates is uncertain and can take many years, with the FDA having substantial discretion in the approval process [213]. - The company has not previously submitted an NDA or BLA to the FDA, which is required before marketing any product candidates in the U.S. [213]. Clinical Trials and Efficacy - In clinical studies, TA-ERT significantly reduced CSF HS-NRE levels by 91.5 ng/mL from baseline at 240 weeks, with most participants normalizing levels within eight weeks of therapy initiation [30]. - Cognitive function in children treated with TA-ERT remained stable over time, contrasting with untreated children who experienced cognitive decline starting around five years of age [31]. - The mean exposure to TA-ERT in clinical studies was 4.2 years, with no deaths reported and the most common treatment-emergent adverse event being vomiting in 100% of participants [34]. - The immediate goal of treatment for Congenital Adrenal Hyperplasia (CAH) is to prevent adrenal crises by replacing missing physiological levels of corticosteroids [50]. - The incidence of classic CAH is estimated at approximately one in 14,000 to 18,000 live births, highlighting the need for effective treatment options [51]. - The Phase 2 clinical trial TAMARIND aimed to explore the efficacy of 400mg twice-daily tildacerfont versus placebo in improving depressive symptoms in MDD patients who are Cortibon-positive, but was discontinued in Q1 2026 due to a serious adverse event [47]. - The TAMARIND Phase 2 study of tildacerfont in MDD was discontinued in Q1 2026 following a serious adverse event involving elevated liver enzymes [198]. - Patient enrollment challenges for clinical trials may lead to delays or abandonment of trials, particularly for rare disorders with limited patient populations [201]. Financial Performance and Funding - For the year ended December 31, 2025, the company incurred a net loss of $39.0 million and used $33.3 million of cash in operations [172]. - As of December 31, 2025, the company had an accumulated deficit of $289.2 million and cash and cash equivalents of $48.9 million [172]. - The company expects to continue generating operating losses and significant cash outflows for at least the next few years [172]. - The company raised net proceeds of $93.4 million from its IPO in October 2020 and $50.9 million from a private placement in February 2023 [175]. - In October 2025, the company entered into a Securities Purchase Agreement, resulting in total net proceeds of $46.6 million [175]. - The company has a Loan Agreement with Avenue Capital, providing term loans of up to $50.0 million, contingent on achieving certain regulatory milestones [176]. - The company will require substantial additional financing to develop its product candidates and implement its operating plan [174]. - The company may need to raise additional funds sooner if it chooses to expand more rapidly than currently anticipated [178]. - The company’s ability to continue as a going concern is in doubt due to insufficient working capital for planned operations over the next twelve months [172]. - The company reported net losses of $39.0 million and $53.0 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $289.2 million as of December 31, 2025 [184]. - The company anticipates continuing to incur significant net losses for the foreseeable future as it advances clinical development and seeks regulatory approvals for its product candidate, TA-ERT [185]. Market and Competitive Landscape - The company has not yet generated any product revenue and has no products approved for commercial sale to date [184]. - The company faces significant competition from other biotechnology and pharmaceutical companies, which may impact its operating results and market position [194]. - The company may need to seek additional capital through equity offerings, debt financings, or strategic partnerships, which could dilute existing stockholders' interests [181]. - The company has a limited operating history and has not yet demonstrated the ability to successfully complete clinical development or commercialize products [182]. - The company is subject to various risks and uncertainties in drug development, which may affect its ability to achieve profitability [185]. Regulatory and Compliance Challenges - The company is subject to extensive regulation by government authorities in the U.S. and other countries, impacting all aspects of drug development and marketing [83]. - The company’s commercial success will depend on its ability to maintain patent protection and proprietary rights, as well as to navigate regulatory approvals effectively [76][83]. - The company may be subject to significant penalties, including civil, criminal, and administrative penalties, if found in violation of healthcare laws [124]. - Third-party payors are increasingly challenging drug prices and may limit coverage to specific products on an approved list, impacting sales [127]. - Participation in governmental programs may require the company to engage in discount and rebate programs, potentially lowering product prices [128]. - The process for determining coverage by third-party payors may differ from the process for setting drug prices and reimbursement rates [127]. - The company may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost-effectiveness of its products [127]. - The Inflation Reduction Act of 2022 requires the U.S. Department of Health and Human Services to negotiate prices for certain single-source biologics, potentially affecting up to 20 products annually [129]. - The downward pressure on healthcare costs, particularly for prescription drugs, has intensified, leading to higher barriers for new product entries [131]. - The U.S. government is pursuing policies to reduce drug prices, including Most-Favored Nation pricing, which may impact manufacturers' global pricing strategies and profitability [135]. - The Health Technology Assessment Regulation in the EU will apply to new active substances for cancer treatment starting January 12, 2025, with further expansions planned [138]. - The implementation of cost containment measures may hinder the ability to generate revenue and achieve profitability for approved products [139]. - Compliance with evolving data privacy laws, such as the GDPR, imposes significant operational challenges and potential penalties for noncompliance [141]. - The U.S. Foreign Corrupt Practices Act mandates accurate accounting and internal controls for international operations, impacting compliance obligations [144]. - The Clinical Trials Regulation in the EU aims to streamline clinical trial authorizations and improve transparency, effective from January 31, 2025 [146]. - The marketing authorization process in the EU requires submission of a Marketing Authorization Application, which can only be granted to applicants established in the EU [149]. Intellectual Property and Patent Strategy - As of December 31, 2025, the company has acquired rights to 19 patent families, including 26 issued U.S. patents and 216 granted patents in various markets outside the United States [68]. - The patent portfolio covering TA-ERT is expected to expire in 2033-2034, while the patent for tildacerfont is expected to expire in 2027, absent any extensions [69][72]. - The company has licensed 2 patent families from HBM Alpha Therapeutics, including 2 pending U.S. patent applications and 11 pending applications in various markets outside the United States [70]. - The company is required to pay tiered royalties on annual worldwide net sales of licensed products, with rates ranging from high-single digits to low double digits for MPS IIIB products [60]. - The BioMarin License Agreement includes obligations to pay up to $88.0 million upon achieving certain development and regulatory milestones, and up to $100.0 million per licensed product upon achieving certain sales milestones [60].